Achieving a better cure for cancer

More info


CiMaas develops immunotherapy for cancer by optimally engaging the immune system.

Read more about CiMaas Immunotherapy products,
or watch our video.

News /

CiMaas reaches next milestone in NK cell expansion and function

CiMaas successfully expands Natural Killer (NK) cells to clinically relevant numbers using a 2-week protocol. Starting from 200 ml peripheral blood, NK are expanded to numbers meeting the expected clinically required 10.E8 cells/kg, with multiple infusions. This makes the expansion method developed directly applicable for clinical application of the produced NK cells in anti-cancer therapies.